combin
antimicrobi
antiinflammatori
properti
macrolid
azithromycin
improv
clinic
outcom
infant
hospitalis
moder
sever
bronchiol
coinfect
respiratori
pathogen
alter
infant
immun
respons
respons
differ
seen
clinic
recoveri
infant
bronchiol
assess
efficaci
singl
dose
azithromycin
improv
clinic
cours
moder
sever
bronchiol
assess
supplement
oxygen
requir
length
hospit
stay
b
reduc
risk
respiratori
ill
within
month
bronchiol
episod
c
profil
immunopatholog
bronchiol
presenc
absenc
coexist
respiratori
infect
signific
bronchiol
common
lower
respiratori
tract
infect
infanc
primarili
caus
infect
respiratori
epitheli
cell
respiratori
syncyti
viru
rsv
although
respiratori
virus
includ
adenoviru
parainfluenza
influenza
human
metapneumoviru
may
also
contribut
bronchiol
characteris
extens
inflamm
lower
airway
associ
increas
mucu
product
necrosi
epitheli
tissu
clinic
bronchiol
manifest
presenc
tachypnoea
wheez
andor
crepit
preced
upper
respiratori
ill
bronchiol
without
pneumonia
common
caus
admiss
children
age
central
australian
studi
describ
preval
approxim
per
children
rsv
bronchiol
preval
caus
bronchiol
would
inde
higher
set
coexist
pneumonia
high
indigen
children
royal
darwin
hospit
rdh
major
children
bronchiol
also
treat
antibiot
coexist
pneumonia
like
relat
high
carriag
rate
earli
acquisit
respiratori
pathogen
indigen
children
compar
nonindigen
children
review
chart
children
hospitalis
bronchiol
rdh
found
readmiss
rate
indigen
children
next
bronchiol
episod
within
unpublish
major
children
hospitalis
bronchiol
retriev
remot
commun
impact
ill
cost
plu
social
disloc
signific
furthermor
recurr
lower
respiratori
tract
infect
independ
signific
risk
factor
later
develop
bronchiectasi
lower
pulmonari
function
later
year
addit
sever
hospitalis
episod
oxygen
requir
length
hospit
stay
also
risk
factor
develop
bronchiectasi
retrospect
chart
review
found
indigen
infant
hospitalis
bronchiol
sever
bronchiol
nonindigen
infant
unpublish
indigen
infant
sever
score
present
number
day
requir
oxygen
length
hospitalis
significantli
wors
longer
nonindigen
infant
respect
thu
intervent
efficaci
reduc
sever
bronchiol
andor
readmiss
bronchiol
indigen
children
would
benefici
short
long
term
outcom
publish
randomis
control
trial
rsvbronchiol
contrast
result
turkish
studi
hospitalis
infant
clarithromycin
effect
reduc
length
hospit
stay
sever
ill
oxygen
use
well
readmiss
rate
infant
moder
sever
bronchiol
howev
european
base
studi
primarili
netherland
azithromycin
efficaci
infant
hospitalis
bronchiol
suspect
mani
possibl
reason
differ
efficaci
major
reason
differ
found
relat
set
ie
infant
turkey
like
concomit
bacteri
infect
compar
affluent
european
group
childhood
bronchiectasi
remain
problem
turkey
similar
found
indigen
children
live
nt
highli
like
indigen
infant
set
similar
turkish
infant
howev
import
establish
whether
azithromycin
inde
efficaci
set
given
extrapol
data
develop
countri
may
result
poorer
outcom
bronchiol
nt
indigen
children
complic
known
earli
colonis
nasopharynx
bacteri
pathogen
notabl
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
whilst
macrolid
azithromycin
sever
benefit
clarithromycin
northern
territori
set
azithromycin
activ
rang
respiratori
pathogen
colonis
nt
indigen
infant
young
age
particular
gram
neg
bacteria
includ
h
influenza
also
azithromycin
current
wide
use
northern
territori
bronchiectasi
trachoma
sexual
transmit
diseas
longer
half
life
better
tissu
penetr
clarithromycin
thu
requir
much
shorter
treatment
regim
weekli
dose
shown
suffici
tissu
effect
last
week
pharmacodynamickinet
properti
azithromycin
superior
clarithromycin
elect
use
azithromycin
rather
clarithromycin
macrolid
famili
antibiot
addit
antibacteri
properti
possess
potent
antiinflammatori
properti
also
influenc
bacteri
biofilm
laboratori
studi
show
macrolid
directli
dampen
airway
inflamm
inhibit
migrat
neutrophil
respiratori
epithelium
inhibit
product
proinflammatori
cytokin
mediat
given
acquisit
colonis
respiratori
pathogen
occur
earli
indigen
infant
earli
week
current
data
biofilm
present
peopl
chronic
upper
respiratori
infect
propos
azithromycin
may
valuabl
intervent
clinic
outcom
indigen
infant
hospitalis
bronchiol
children
admit
paediatr
ward
rdh
tth
diagnosi
bronchiol
identifi
record
studi
log
elig
children
determin
use
elig
criteria
children
enrol
studi
elig
children
consent
children
meet
elig
criteria
record
studi
log
plainlanguag
educ
tool
use
explain
studi
primari
caregiv
clinic
elig
infant
inform
consent
given
infant
enrol
randomis
receiv
either
singl
oral
dose
azithromycin
syrup
perkg
equival
volum
placebo
syrup
obtain
inform
consent
complet
consent
form
give
copi
inform
sheet
carer
complet
enrol
form
much
demograph
medic
histori
possibl
carer
use
date
birth
indigen
statu
data
determin
treatment
strata
possibl
strata
strata
indigen
month
less
strata
non
indigen
month
less
strata
indigen
older
month
strata
non
indigen
older
month
complet
chart
notif
sticker
stick
child
medic
chart
doubleblind
randomis
placebocontrol
trial
conceal
alloc
studi
medic
assign
label
b
c
two
label
assign
placebo
azithromycin
two
assign
azithromycin
independ
person
studi
menzi
school
health
research
neither
studi
team
research
hospit
staff
parent
know
treatment
group
placebo
azithromycin
infant
assign
result
analys
placebo
azithromycin
specif
manufactur
idt
australia
limit
melbourn
victoria
similar
smell
tast
activ
azithromycin
manufactur
placebo
recruitmentfollow
microbiolog
data
analysi
public
feedback
stakehold
primarili
nhmrc
fund
intern
studi
bronchiectasi
indigen
children
treatment
alloc
list
comput
gener
use
stratifi
block
randomis
sheet
correspond
treatment
strata
treatment
alloc
conceal
black
sticker
upon
enrol
infant
assign
next
treatment
appropri
stratifi
list
treatment
b
c
reveal
identifi
correct
strata
write
child
name
hrn
next
avail
line
number
refer
child
studi
identif
number
remov
sticker
reveal
studi
medic
alloc
letter
b
c
record
child
chart
notif
sticker
enrol
form
treat
physician
complet
abi
script
order
medicationplacebo
medic
chart
dose
medic
script
found
studi
document
given
physician
abi
studi
staff
abi
script
taken
pharmaci
abi
studi
staff
medic
dispens
take
medic
back
paediatr
ward
inform
nurs
look
child
child
enrol
studi
children
enrol
weekend
pleas
ensur
script
taken
pharmaci
ensur
pharmaci
enough
time
dispens
administersupervis
administr
first
dose
medic
nasopharyng
swab
one
nasopharyng
swab
obtain
prior
administr
studi
medic
second
nasopharyng
swab
obtain
hour
post
administr
studi
medic
swab
store
separ
vial
stggb
medium
store
degre
prior
dispatch
menzi
laboratori
process
plan
enrol
infant
total
children
stratifi
age
month
less
month
indigen
statu
indigen
non
indigen
site
darwin
townsvil
mean
length
stay
bronchiol
royal
darwin
hospit
hour
detect
mean
differ
hour
length
stay
treatment
group
alpha
power
requir
sampl
size
infant
per
group
particip
studi
complet
voluntari
particip
may
choos
refus
particip
studi
parent
reassur
care
child
compromis
way
particip
particip
studi
complet
voluntari
particip
may
choos
withdraw
stage
without
give
reason
children
enrol
studi
manag
hospit
staff
accord
standard
clinic
practic
manag
bronchiol
exempt
receiv
care
manag
protocol
specifi
attend
physician
standardis
sheet
use
collect
clinic
data
demograph
inform
medic
histori
obtain
primari
caregiv
hospit
record
primari
secondari
outcom
measur
describ
monitor
medic
chart
acut
studi
endpoint
reach
defin
hour
supplement
oxygen
infant
feed
well
clinic
assess
data
includ
oxygen
requir
level
physiolog
measur
clinic
sever
score
respiratori
rate
accessori
muscl
use
degre
wheez
physiolog
measur
temperatur
heart
rate
requir
therapi
iv
fluid
nutrit
antibiot
addit
routin
investigatori
paramet
fbc
chest
xray
find
record
swab
microbiolog
analysi
store
stggb
accord
guidelin
presenc
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
identifi
use
cultur
method
establish
menzi
laboratori
antibiot
resist
phenotyp
also
determin
pre
post
studi
medic
administr
addit
nucleic
acid
extract
ml
nasopharyng
swab
specimen
use
high
pure
viral
nucleic
acid
kit
roch
diagnost
australia
accord
manufactur
instruct
monospecif
pcr
revers
transcriptas
pcr
rtpcr
method
use
detect
mycoplasma
pneumonia
chlamydia
pneumonia
coronavirus
bocaviru
human
metapneumoviru
hmpv
wherea
multiplex
pcr
rtpcr
use
detect
adenoviru
parainfluenza
influenza
b
respiratori
syncyti
viru
rsv
method
previous
valid
qld
paediatr
infecti
diseas
laboratori
npa
collect
standard
clinic
manner
frozen
upon
thaw
nucleic
acid
extract
ml
npa
specimen
use
high
pure
viral
nucleic
acid
kit
roch
diagnost
australia
accord
manufactur
instruct
monospecif
pcr
revers
transcriptas
pcr
rtpcr
method
use
detect
mycoplasma
pneumonia
chlamydia
pneumonia
coronavirus
bocaviru
human
metapneumoviru
hmpv
wherea
multiplex
pcr
rtpcr
use
detect
adenoviru
parainfluenza
influenza
b
respiratori
syncyti
viru
rsv
method
previous
valid
qld
paediatr
infecti
diseas
laboratori
data
analysi
primari
outcom
length
stay
bronchiol
episod
primari
outcom
length
hospit
stay
compar
infant
receiv
placebo
azithromycin
use
nonparametr
analysi
data
within
indigen
statu
analys
separ
length
time
supplement
oxygen
readmiss
hospit
within
month
episod
clinic
secondari
outcom
laboratori
data
also
analys
use
nonparametr
analysi
categor
data
compar
use
chi
squar
fisher
exact
inform
collect
studi
particip
treat
strictli
confidenti
access
studi
personnel
data
store
restrictedaccess
build
tth
sent
menzi
school
health
research
lock
file
cabinet
passwordprotect
electron
databas
studi
particip
issu
numer
code
identifi
public
data
store
year
child
reach
age
whichev
greater
sampl
use
research
purpos
nasopharyng
swab
nasopharyng
aspir
process
store
restrictedaccess
laboratori
menzi
school
health
research
train
studi
personnel
sampl
sent
qpid
laboratori
analysi
transport
courier
identifi
numer
code
qualiti
controlqu
assur
studi
conduct
accord
nhmrc
guidelin
ethic
matter
aborigin
torr
strait
island
health
research
note
guidanc
good
clinic
practic
declar
helsinki
ethic
approv
clinic
trial
protocol
committe
review
protocol
subsequ
amend
sought
prior
implement
adequ
train
experienc
personnel
employ
trial
relat
activ
document
way
curriculum
vita
kept
menzi
school
health
research
safeti
profil
measur
incid
intens
relationship
studi
drug
advers
event
seriou
advers
event
advers
event
untoward
medic
occurr
experienc
particip
undergo
treatment
clinic
trial
one
week
dose
studi
medicin
advers
event
includ
temporari
moder
discomfort
disabl
particip
seriou
advers
event
defin
event
fatal
life
threaten
perman
disabl
particip
admiss
hospit
overdos
requir
addit
medic
manag
side
effect
azithromycin
rare
list
mim
annual
includ
nausea
vomit
diarrhoea
abdomin
pain
rare
potenti
seriou
side
effect
list
angioedema
cholestat
jaundic
children
enrol
studi
admit
tth
rdh
monitor
accord
hospit
protocol
child
progress
monitor
daili
studi
staff
via
medic
chart
nurs
unit
manag
classif
report
seriou
advers
event
sae
investig
assess
determin
whether
event
caus
administr
studi
medicin
causal
assess
definit
base
standard
criteria
sae
investig
chief
investig
consult
independ
safeti
monitor
causal
assign
use
definit
find
investig
report
independ
safeti
monitor
within
time
period
specifi
standard
format
see
sae
brief
case
summari
sae
causal
classif
likelycertain
probabl
possibl
must
also
report
chief
investig
chair
dsmb
within
hour
determin
dsmb
independ
group
expert
advis
studi
investig
member
dsmb
serv
individu
capac
provid
expertis
recommend
guid
clinic
trial
elect
member
dsmb
becom
independ
safeti
monitor
studi
dsmb
unblind
review
event
ie
mild
moder
sever
lifethreaten
event
whether
relat
unrel
administr
studi
drug
dsmb
meet
person
via
telephon
link
start
trial
sixmonthli
basi
dsmb
also
review
seriou
advers
event
expediti
manner
report
vote
member
dsmb
posit
primari
dsmb
contact
seriou
advers
event
report
lias
chief
investig
health
care
provid
ensur
best
standard
care
provid
particip
review
classif
sae
direct
investig
necessari
provid
advic
inform
requir
assign
causal
public
report
result
outcom
trial
accord
menzi
public
polici
public
result
subject
fair
peerreview
authorship
given
person
provid
signific
input
concept
design
execut
report
research
accord
menzi
statement
record
integr
person
author
consist
definit
exclud
author
without
permiss
write
authorship
discuss
research
prior
studi
commenc
soon
possibl
thereaft
review
whenev
chang
particip
conflict
aris
disput
authorship
review
menzi
director
acknowledg
given
collabor
institut
hospit
individu
organ
provid
financ
facil
annual
report
submit
appropri
human
research
ethic
committe
regular
studi
progress
report
made
avail
clinic
nurs
staff
royal
darwin
hospit
tth
final
report
made
avail
stakehold
includ
royal
darwin
hospit
menzi
school
health
research
fund
bodi
hrec
studi
particip
individu
identifi
public
written
oral
infant
month
age
involv
studi
studi
explain
verbal
child
carer
base
inform
sheet
consent
flipchart
parentsguardian
sign
consent
form
carer
elig
children
fulli
inform
studi
data
collect
procedur
possibl
risk
involv
take
studi
medic
azithromycin
placebo
nasopharyng
swab
collect
train
member
studi
team
nasopharyng
aspir
perform
part
hospit
manag
bronchiol
perform
hospit
staff
azithromycin
current
use
northern
territori
children
chronic
suppur
lung
diseas
trial
regist
australian
new
zealand
clinic
trial
regist
march
